Xenon Pharmaceuticals Inc
XENE
Company Profile
Business description
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Contact
200-3650 Gilmore Way
BurnabyBCV5G 4W8
CANT: +1 604 484-3300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
327
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,890.80 | 74.40 | 0.84% |
CAC 40 | 7,822.00 | 99.91 | 1.29% |
DAX 40 | 24,370.93 | 361.55 | 1.51% |
Dow JONES (US) | 44,393.38 | 138.60 | 0.31% |
FTSE 100 | 8,972.64 | 46.09 | 0.52% |
HKSE | 24,498.95 | 18.81 | -0.08% |
NASDAQ | 20,891.01 | 160.52 | 0.77% |
Nikkei 225 | 39,901.19 | 237.79 | 0.60% |
NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
S&P 500 | 6,289.02 | 25.32 | 0.40% |
S&P/ASX 200 | 8,639.00 | 77.20 | 0.90% |
SSE Composite Index | 3,516.83 | 13.05 | 0.37% |